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Abstract 
Background: Previously, we have shown that transgenic cells bearing the GDNF gene with deleted pre- and pro-
regions (mGDNF) can release transgenic GDNF. The medium conditioned by transgenic cells with mGDNF induced 
axonal growth in rat embryonic spinal ganglion in vitro. Here we demonstrate a neurotrophic effect of mGDNF on 
PC12 cells in vitro as well as its neuroprotective effect on dopaminergic neurons in the substantia nigra pars com-
pacta in vivo as indicated by improved motor coordination and sleep-wakefulness cycle in the MPTP mouse model of 
Parkinson’s disease.
Results: HEK293 cells were transfected with a vector encoding an isoform of the human GDNF gene with deleted 
pre- and pro-regions (mGDNF). This factor in the medium conditioned by the transfected cells was shown to induce 
axonal growth in PC12 cells. The early Parkinson’s disease model was established by injection of the dopaminergic 
pro-neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into C57Bl/6 mice. Transgenic HEK293/mGDNF/
GFP cells were transplanted into the striatum (caudate-putamen) of experimental mice. The sleep-wakefulness cycle 
was studied by continuous EEG and motor activity monitoring 1 and 2 weeks after MPTP injection. After the experi-
ment, the motor coordination of experimental animals was evaluated in the rotarod test, and dopaminergic neurons 
in the substantia nigra pars compacta were counted in cross-sections of the midbrain. MPTP administration lowered 
the number of tyrosine hydroxylase immunopositive cells in the substantia nigra pars compacta, decreased motor 
coordination, and increased the total wake time during the dark period. The transplantation of HEK293/mGDNF cells 
into the caudate-putamen 3 days prior to MPTP injection smoothed these effects, while the control transplantation of 
HEK293 cells showed no notable impact.
Conclusions: Transplantation of transgenic cells with the GDNF gene lacking the pre- and pro-sequences can pro-
tect dopaminergic neurons in the mouse midbrain from the subsequent administration of the pro-neurotoxin MPTP, 
which is confirmed by polysomnographic, behavioral and histochemical data. Hence it is released from transfected 
cells and preserves the differentiation activity and neuroprotective properties.
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Background
Glial cell line-derived neurotrophic factor (GDNF) pro-
motes the survival and differentiation of neurons and 
glial cells [1–3]. This GDNF activity can be useful in the 
treatment of neuronal degeneration and loss of differen-
tiation typical for a number of neurodegenerative dis-
eases. GDNF has a pronounced neuroprotective effect on 
dopaminergic neurons and spinal motoneurons [4] and 
induces axonal growth [5].
GDNF is expressed in both neurons and astrocytes 
[6, 7]. It was proposed that elevated GDNF synthesis in 
astrocytes promotes neuronal survival after ischemic [8] 
and excitotoxic damage [6]. The importance of GDNF for 
the maintenance of neuronal viability is also confirmed 
by the transplantability of cerebral tissues in GDNF-defi-
cient mice. Dopaminergic neurons of GDNF−/− mouse 
embryos transplanted into the dorsal striatum of wild 
type mice cannot survive and innervate the striatum after 
MPTP-induced degeneration of their endogenous dopa-
minergic neurons [9]. The significance of GDNF as a neu-
rotrophic factor was also confirmed by a sharp reduction 
of dopaminergic sprouting in the injured striatum after 
antisense inhibition of GDNF expression [10]. Protective 
effect of GDNF on dopaminergic neurons was demon-
strated in several models of Parkinson’s disease [11–15].
The human GDNF gene contains six exons and gen-
erates five isoforms [16]. The encoded GDNF mRNAs 
include the full-length pre-(α)pro-GDNF transcript 
and the pre-(β)pro-GDNF, the latter is shorter by 78 bp 
in region of the pro-domain. The protein encoded by 
pre-(α)pro-GDNF is released from the cell via the con-
ventional pathway through the Golgi apparatus [17]. At 
the same time, the release of the shorter protein encoded 
by pre-(β)pro-GDNF is largely mediated by secretogra-
nin II and Rab3A-positive vesicles and, thus, bypasses 
the Golgi apparatus. Kust et al. [1] demonstrated that the 
deletion of the pre- and pro-regions of the GDNF gene 
does not affect the transgenic factor release from trans-
fected cells. Moreover, the deletion of both pre- and pro-
regions enhances the trophic activity of GDNF. Spinal 
ganglia cultured in the presence of medium conditioned 
by cells transfected with mGDNF demonstrated active 
growth of β-3-tubulin-positive axons by day 4 of culture 
[1].
Here, we studied the effect of transgenic mGDNF 
encoded by the GDNF gene with deleted pre- and pro-
regions in PC12 cells in vitro. Then, the effect of mGDNF-
producer cells on the survival of dopaminergic neurons 
in the mouse substantia nigra was evaluated in vivo using 
the conventional 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) model of Parkinson’s disease [18]. This 
model was used repeatedly for the study of neuroprotec-
tive substances, neurotoxin being administrated in many 
cases after the neuroprotectors [16, 19]. The MPTP effect 
depends on the dose and administration mode. Here, we 
used a single subcutaneous administration of 40  mg/kg 
MPTP, which induces an early clinical stage of Parkin-
son’s disease [19].
The effect of mGDNF-producing transgenic cells was 
evaluated using the rotarod test for motor coordination 
of experimental mice [20]. In addition, we implemented 
a test evaluating early abnormalities of brain function 
through the changes in the sleep-wakefulness cycle. Par-
kinson’s disease is accompanied by a wide range of sleep-
wakefulness cycle abnormalities observed in 45–92  % 
patients. In particular, many patients demonstrate pro-
longed nighttime awakenings and reduced NREM and 
REM sleep [21, 22]. In the MPTP model of early Par-
kinson’s disease, experimental mice also demonstrate 
increased activity and reduced NREM and REM sleep 
at nighttime [23], i.e., in the same period of pineal mela-
tonin production when the corresponding sleep disorders 
are observed in patients [24]. So, this model is adequate 
for studying the effects of various biochemical factors in 
early Parkinson’s disease.
In this work it was demonstrated that transgenic fac-
tor mGDNF lacking pre- and pro-sequences is not only 
secreted by cells and stimulates neurite growth in  vitro 
but also demonstrates neuroprotective properties in the 
neurotoxic model of Parkinson’s disease which had been 
shown several times for the full length GDNF molecule. 
We have found that mGDNF is more secreted by trans-
fected cells than the pre-pro-GDNF. We confirm by our 
work that transgenic factor mGDNF stimulates neurite 
growth and neural differentiation of PC12 cells in vitro. 
Using the experiments with the injection of transgenic 
cells to the mice striatum and subsequent system admin-
istration of MPTP, we have found that the GDNF isoform 
retains its neurotrophic properties also in  vivo when 
the factor is secreted into active intracerebral medium 
which is quite different from the cultural one. Modified 
transgenic factor secreted by the cells injected into stria-
tum makes indirect retrograde effect on substantia nigra 
cells. This indicates that mGDNF can be used for treating 




The mGDNF construct with deleted pre- and pro-
regions and with an EGFP tag was generated by intro-
ducing a HindIII site, a Kozak sequence, and an 
extra start codon upstream of the “m” part as well 
as by removing the stop codon and introducing a 
BamHI site in the 3′ region of mGDNF using PCR. 
The following primers were employed: GdnfHindIII(F) 
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5′-AAGCTTCCACCATGTCACCAGATAAACAA-3′ 
and GdnfBamH1(R)5′-GGATCCCAG ATACATCCACACC 
TTTTAGCGG-3′. The plasmid pGEM-T Easy (Promega) 
containing the full-length human GDNF cDNA [25] was 
used as the template. PCR was performed using the Ter-
sus polymerase (Evrogene) and the following program: 
94  °C for 1.5 min; 25 cycles of 94  °C for 15  s, 57  °C for 
20 s, and 72 °C for 15 s; and final 72 °C for 10 min. The 
resulting 354  bp (118 amino acids) fragment was iso-
lated from agarose gel using a Qiaquick Gel Extraction 
Kit (Qiagen) and cloned into pGEM-T Easy (Promega). 
The HindIII/BamHI fragment of the resulting construct 
pGEM/mGdnf was cloned into the corresponding sites of 
pEGFP-N1 (Clontech). For the control we used construct 
with pre-pro-GDNF, which were prepared using the 
primers T3 (F) 5′-ATTAACCCTCACTAAAGGGA-3′ и Gdnf BamH1 5′-TGGATCCCAGA TACACCACACC 
TTTTAGCGG-3′. This construct was obtained accord-
ing to the protocol described elsewhere [1].
Transgenic cell cultures
Human Embryonic Kidney 293 (HEK293) cell line was 
obtained from the Russian Cell Culture Collection (Insti-
tute of Cytology of the Russian Academy of Sciences, St. 
Petersburg, Russia). HEK293 cells were cultured in com-
plete DMEM (PanEko) supplemented with 10 % fetal calf 
serum (Perbio HyClone), 2  mM  l-glutamine (PanEko), 
and 10  µg/ml gentamicin (PanEko) at 37  °C with 5  % 
CO2 in 25  cm2 Costar flasks. At 70–80  % confluence, 
the cells were transfected with the generated constructs 
using ExGen 500 (Fermentas). The transfected clones 
were selected with 0.4 mg/ml geneticin (G418, Sigma) for 
10 days, after which G418-resistant clones were analyzed 
by PCR for the inserted gene sequences. The transgene 
expression was verified by RT-PCR with the correspond-
ing primers.
RT‑PCR
Total RNA was isolated using Tri reagent (Sigma), treated 
with DNAseI (Thermo Scientific) (1 U per 1  μg RNA), 
and used for reverse transcription with M-MuLV Reverse 
Transcriptase and oligo (dT) primer. The efficiency of 
reverse transcription was evaluated by PCR with the 
primers for GAPDH (F, 5′-GGCCATGAGGTCCACC 
ACCCTGTTGCTGTA-3′; R, 5′-CCCCTGGCCAAGG 
TCATCCATGACAACTT-3′) and for neomycin (F, 
5′-ATGATTGAACAAGATGGATT-3′; R, 5′-TCAGAAG 
AACTCGTCAAGAA-3′. RNA not subjected to reverse 
transcription was used as a negative control. The effi-
ciency of transgene expression was evaluated by PCR 
with the following primers: GdnfHindIII(F) 5′-AAGCTTC-
CACCATGTCACCAGATAAACAA-3′ and gfp (R) 
5′-AATAAAGCTTGCATGGCGGTAATACG-3′. The 
PCR amplification program consisted of 94 °C for 2 min; 
30 cycles of 93 °C for 10 s, 58 °C for 20 s, and 72 °C for 
30 s; and final 72 °C for 5 min.
ELISA
The 24-h culture media of transgenic HEK293/mGDNF/
GFP, transgenic HEK293/pre-pro-GDNF/GFP, and 
HEK293 (control) were used in the assay. GDNF was 
quantified using the GDNF Emax ImmunoAssay System 
(Promega) and a microplate reader Synergy 4 (Tecan) 
according to the manufacturer’s protocol.
Analysis of mGDNF effect on PC12 cells
PC12 cells are a clonal cell line derived from a pheochro-
mocytoma of the rat adrenal medulla. They are used as a 
model for the study of neuronal differentiation [26]. PC12 
(ATCC CRL1721) cells were tested for neuronal sprout-
ing after the exposure to conditioned medium contain-
ing GDNF with deleted pre- and pro-regions. Transgenic 
HEK293 cells were plated on 25  cm2 flasks and, after 
reaching confluence of about 60 %, the complete medium 
was replaced with serum-free DMEM. After 72 h of cul-
ture at 37 °C, the conditioned medium was harvested and 
filtered through a 0.22 nm filter.
PC12 cells were plated at 3 × 104 cells/well on four-well 
plates coated with rat tail type I collagen in RPMI1640 
containing 10 % horse serum, 2 mM l-glutamic acid, and 
100 µg/ml streptomycin. After 4 h of culture, the medium 
was replaced with that conditioned by transgenic HEK/
mGDNF/GFP cells. The medium conditioned by untrans-
fected HEK293 cells for 72  h was used as control. The 
concentration of chimeric GDNF proteins was evaluated 
in the media conditioned by transgenic HEK293 cells for 
further analysis. This concentration was confirmed by 
ELISA. Based on the obtained data, the concentration 
of ~1.25  ng/ml was used to analyze the chimeric pro-
tein activity in  vitro. The following controls were used: 
(1) medium conditioned by HEK293 cells transgenic for 
GFP; (2) medium supplemented with 1.25 ng/ml recom-
binant GDNF (SantaCruz); (3) unconditioned complete 
culture medium. After a 3-day culture in conditioned or 
control medium, PC12 cells were fixed in 4 % formalde-
hyde and analyzed by phase contrast microscopy under 
an inverted microscope Olympus IX81. Then these cells 
were stained using the primary polyclonal antibodies 
against β-3-tubulin (Abcam) and secondary Cy2-con-
jugated donkey anti-rabbit antibodies. After washing in 
PBS, cells were mounted in glycerol and analyzed under 
an inverted fluorescent microscope Olympus IX81. The 
proportion of cells with axons equal to or longer than the 
small diameter of the cell was counted on phase contrast 
and fluorescent images using the ImageTool software 
(UTHSCSA) [27]. Five counts including 100–120 cells 
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were carried out for each studied construct. The obtained 
data were analyzed using the SPSS software (IBM, USA).
Cell transplantation and electrode implantation 
for electroencephalographic analysis of the sleep‑waking 
cycle
The neuroprotective effect of transgenic mGDNF 
encoded by the GDNF gene with deleted pre- and pro-
regions on the viability of dopaminergic neurons in the 
substantia nigra pars compacta was studied in the early 
Parkinson’s disease model. Transgenic cells were injected 
into the striatum (the caudate nucleus/putamen region) 
of mice 3  days prior to subcutaneous administration of 
40 mg/kg of the proneurotoxin MPTP.
Four groups of animals were studied:
1. Animals transplanted with transgenic HEK293/
mGDNF/GFP cells 3  days prior to MPTP injection 
(N = 10).
2. Animals transplanted with HEK293/GFP cells with-
out the GDNF gene 3 days prior to MPTP injection 
(N = 10).
3. Animals transplanted with transgenic HEK293/
mGDNF/GFP cells with no subsequent MPTP injec-
tion (N = 5).
4. Animals injected with MPTP without preliminary 
cell transplantation (N = 11).
All in  vivo experiments were approved by the Ethics 
Committee of Moscow State University. Animals anes-
thetized by chloral hydrate were placed in a stereotaxic 
frame. Transgenic HEK293/mGDNF/GFP cells were 
injected into the striatum of C57BL/6j mice at the age of 
2.5–3 months weighing 25–30 g (groups 1 and 3). A sus-
pension containing about 150,000 cells in 1 µl of Hanks 
solution was bilaterally injected into the brain. The injec-
tion was performed slowly (over a period of 3 min) with 
a microsyringe at coordinates AP 0 mm and ML 2.5 mm 
(the caudate nucleus/putamen region). The needle was 
inserted to a depth of 2.5  mm and withdrawn in steps 
to a depth of 1.5  mm. HEK293/GFP cells were injected 
similarly into animals of group 3. Next, four epidural 
electrodes were permanently implanted for electroen-
cephalographic (EEG) monitoring in the frontal and 
parietal neocortex. The reference electrode was placed 
on the nasal bone. Animals of group 4 were not trans-
planted with cells, while the electrodes were implanted 
as described above. After implantation, animals were 
placed into small individual soundproof boxes equipped 
with highly sensitive module video cameras attached to 
a video recorder, which was consequently connected to a 
PC via USB port. Animals were kept under a 12/12 light/
dark cycle (09–21  h, bright white light; 21–09, dim red 
light), temperature 22–24 °C, and free access to food and 
water.
Each animal was attached via a flexible cable to a min-
iature digital two-channel biopotential amplifier supplied 
with a three-axis accelerometer (for mechanographic 
monitoring) attached via a flexible spring to an inde-
pendent power supply, which was consequently attached 
to rotatable hook in the box ceiling. This construc-
tion allowed three-axis motions of the amplifier plate 
(30 × 28 × 7 mm in size and 8 g in weight) in response 
even to faint movements of the animal. The digitization 
frequencies of the EEG and accelerometer signals were 
250 and 50  Hz, respectively. The signal from wireless 
amplifiers was transmitted via Bluetooth channel to the 
recording computer and visualized using the modified 
open-source software EDF browser [28]. The EEG and 
accelerometer bandwidths were set equal to 1–20 and 
1–12  Hz, respectively. The animal behavior and motor 
activity were also monitored by video tracking. Animals 
of group 4  had a 7-day recovery period after implanta-
tion. After this period, the EEG (background) and mech-
anographic monitoring was continuously performed for 
24 h. Such monitoring was repeated 7 and 14 days after 
MPTP administration. Experimental conditions allowed 
no long recovery period and, thus, no background EEG 
recording for animals of the first three groups. Accord-
ingly, only the dynamics of the sleep-wakefulness cycle 
was evaluated 7 and 14 days after MPTP administration 
in comparison to the baseline records in group 4 animals.
MPTP administration and analysis of its effects
Three days after cell transplantation and electrode 
implantation, animals of groups 1, 2, and 4 were subcu-
taneously injected 40 mg/kg of the dopaminergic proneu-
rotoxin MPTP (Sigma, St. Louis, MO, USA). One and two 
weeks later, EEG and mechanographic (by accelerometer) 
records were made. The polysomnograms (EEG + mech-
anogram) obtained for all animals were visually evalu-
ated for 20-s epochs. Wake as well as NREM and REM 
sleep stages were identified using the standard criteria: 
wake, desynchronized cortical EEG, 5–7  Hz hippocam-
pal theta-rhythm in the parietal (hippocampal projec-
tion) EEG, and high accelerometer signal; NREM sleep, 
high delta and sigma EEG activity and low accelerometer 
signal; REM sleep, very high and regular 6–8  Hz theta-
rhythm in the parietal-hippocampal EEG and zero accel-
erometer signal [29]. The data obtained were analyzed by 
nonparametric statistical methods using the GraphPad/
Prism-4.02 software (Friedman and Kruskal–Wallis anal-
ysis of variance, post hoc Dunn’s test, and Wilcoxon and 
Mann–Whitney tests).
After the experiment, the motor coordination of exper-
imental animals was tested on a Rotarod (TSE Systems, 
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Bad Homburg, Germany). Animals were exposed to 
6  rpm for 10  min, after which the rotational speed was 
increased in steps of 1 rpm every 30 s until the animal fell 
onto the tray with wood shavings. The time of falling and 
velocity were recorded.
Fifteen days since MPTP administration (18 days after 
transgenic cells injection) the animals were anesthe-
tized again and perfused through the heart with PBS and 
then with 4 % formaldehyde in PBS. The brain was iso-
lated, fixed again in formaldehyde for 12  h at 4  °C, and 
soaked in 30  % sucrose in PBS for 24  h. The cryotome 
coronal sections of the brain (40  μm) were mounted 
in PBS. Four series of sections were prepared for each 
brain. The sections in antifreeze solution were stored 
at −20  °C until staining. Every fourth section contain-
ing the substantia nigra was immunohistochemically 
stained for tyrosine hydroxylase (TH) using monoclonal 
antibodies (Sigma) diluted 1:200 in PBS with 2  % nor-
mal horse serum, 0.5 % Triton X-100, and 0.01 % sodium 
azide (Sigma). Free-floating sections were incubated in 
primary antibodies at 4  °C for 48 h. After incubation in 
biotinylated horse anti-mouse antibodies diluted 1:100 
(Vector Labs, Burlingame, CA, USA) and then in ABC 
diluted 1:200 (Vector Labs), the standard staining for 
peroxidase was performed using PBS with 0.03 % diam-
inobenzidine (Sigma) and 0.01 % hydrogen peroxide. The 
stained sections were mounted on slides in 50 % glycerol 
and covered with slips. TH-immunopositive (TH+) cells 
were quantified on an Olympus IX81 microscope with 
a computer-controlled motorized stage (Märzhäuser, 
Wetzlar, Germany) and an Olympus DP72 digital cam-
era (Olympus, Münster, Germany). Cells were counted 
using the Cell* software (Olympus Soft Imaging Solution, 
Münster, Germany). After obtaining an overview of the 
compact part of the substantia nigra (SNC) and the ven-
tral tegmental area (VTA) at a low magnification (10× 
objective), TH+ cells were counted using the optical 
fractionator method [30] at a higher magnification (40× 
objective). The 50 × 50 µm counting frame was shifted in 
200 µm steps in both X- and Y-directions within the ven-
tral part of the midbrain. At each position of the count-
ing frame, the focal plane was shifted in the Z direction 
by 30  µm. An uninformed operator counted unstained 
nuclei of TH+ cells in counting frames.
Western blot hybridization
To know how long the transgenic HEK293/mGDNF/GFP 
cells can survive in striatum and produce fusion protein 
mGDNF/GFP we used Western Blot analysis. Two, three, 
five and eighteen days since administration of transgenic 
cells we cut out fragments of mouse striatum in a volume 
of 3–4 mm3 which include the site of injection, then pow-
dered them in a liquid nitrogen and lysed in the following 
buffer (100 µl per 106 cells): 60 mM Tris–HCl (pH 6.8), 
25 % (v/v) glycerol, 2 % SDS, 5 % (v/v) 2-mercaptoethanol, 
and 0.01 % (w/v) bromophenol blue. Protein concentra-
tion was determined by Bradford assay and 40 µg protein 
samples were loaded onto a 10  % gel and analyzed by 
SDS-PAGE. Proteins were transferred to a Hybond ECL 
membrane (Amersham, Buckinghamshire, UK) using a 
Mini trans-Blot cell (Bio-Rad #170-3930) according to 
the manufacturer’s instructions in the buffer containing 
25 mM Tris, 192 mM glycine, and 20 % (v/v) methanol, 
pH 8.3 at 100 V for 1 h. The membrane was stained with 
Ponceau Red and thoroughly rinsed with TBS-T buffer. 
Then the membrane was incubated on a shaker in 5  % 
defatted milk powder in TBS-T at room temperature for 
30  min and washed three times with TBS-T for 5  min. 
GDNF was detected using monoclonal antibodies against 
GDNF (D20, Santa Cruz Biotechnology, Dallas, USA). 
The membrane was incubated with the primary antibod-
ies at 4 °C overnight and washed with TBS-T. Incubation 
with the secondary peroxidase-conjugated antibodies 
(1:3000) was carried out at room temperature for 1 h, and 
the membrane was washed with TBS-T. GDNF detection 
was performed using an ECL Advance Western Blotting 
Detection Kit (Amersham) according to the manufactur-
ers’ instructions. In each group there were 3 mice with 
the same surviving time since the cell administration. The 
intensity of the bands were measured using ImageJ [31].
Statistical analysis
Data are presented as mean ± SEM. The statistical analy-
sis was performed using the SPSS software. The values 
were compared by one-way ANOVA followed by Tukey’s 
multiple comparisons test. Statistical significance was 
accepted at p < 0.05.
Results
Quantitative analysis of GDNF released from transgenic 
cells
The transgenic culture of human embryonic kidney cells 
HEK293 producing mGDNF/GFP was obtained using 
the protocol described elsewhere [1]. The release of the 
fusion mGDNF/GFP protein from transgenic HEK293 
cells was evaluated by ELISA. Each experiment was 
done in triplicates. The medium conditioned by untrans-
fected HEK293 cells was used as control. HEK293 cells 
were cultured in DMEM containing 10  % fetal serum, 
2  mM  l-glutamine at 37  °C in a CO2 incubator. GDNF 
was quantified using the GDNF Emax ImmunoAssay Sys-
tem. mGDNF/GFP was shown to be released to the cul-
ture medium of the transgenic cells. The level of released 
mGDNF/GFP was much higher than that of the full-
length pre-pro-GDNF/GFP (Fig.  1). Likewise, mGDNF 
level in the conditioned medium was also much higher 
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compared to pre-pro-GDNF/GFP. The observed experi-
mental differences were significant at p < 0.05 (one-way 
ANOVA).
The influence of conditioned media containing mGDNF/
GFP on neurite outgrowth in PC12 cells
The efficiency of conditioned media containing mGDNF/
GFP was analyzed using PC12 cells. After 3-day culture 
in conditioned medium with GDNF lacking the pre- 
and pro-regions as well as with recombinant GDNF, the 
proportion of cells with axons (exceeding the neuronal 
body size) was significantly higher than that in control 
cultures at p < 0.05 (Fig. 2). One-way ANOVA indicated 
significant differences between the control cells cultured 
in medium conditioned by untransformed HEK293 cells 
and those cultured in the normal unconditioned medium. 
The proportion of cells with axons cultured in medium 
conditioned by transgenic HEK293/mGDNF/GFP cells 
was substantially and significantly higher than that in 
control cells cultured in unconditioned medium. The dif-
ference between cells cultured in media conditioned by 
transgenic HEK293/mGDNF/GFP and HEK293/pre-pro-
mGDNF/GFP was also significant. The highest propor-
tion of cells with axons was observed in cells cultured in 
medium conditioned by HEK293/mGDNF/GFP.
Figure  3 demonstrates immunohistochemical staining 
of PC12 cells exposed to media conditioned by HEK293 
cells transfected with pre-pro-GDNF/GFP and mGDNF/
GFP, by untransfected HEK293 (HEK), and in uncon-
ditioned medium. Thus, the removal of the pre- and 
pro-regions did not affect the transport of this GDNF 
modification from the cell and improved the inductive 
properties of the factor.
Analysis of protective properties of the GDNF 
modification in vivo using the mouse MPTP model 
of Parkinson’s disease
Histological studies of changes in the substantia nigra 
and ventral tegmental area
Analysis of sections prepared from animals sacrificed 
17  days after the injection of 40  mg/kg of MPTP dem-
onstrated significant changes in the number of dopa-
minergic neurons in the substantia nigra pars compacta 
between the experimental and control animals (Figs. 4, 5). 
Control animals injected with MPTP alone demonstrated 
a significant decrease in the number of TH+ neurons in 
the ventral midbrain. In SNC, the number of TH+ neu-
rons decreased by 78 %; in VTA, by 54 % relative to con-
trol; while the overall number of TH+ neurons decreased 
by 67  % (Fig.  5). The number of TH+ neurons in these 
midbrain structures in animals transplanted with cells 
expressing the GDNF gene with deleted pre- and pro-
sequences (HEK293/mGDNF/GFP + MPTP) was signifi-
cantly higher than that in animals of two control groups 
Fig. 1 Quantitative analysis of GDNF in medium conditioned by transgenic and control untransfected HEK293 using ELISA. (HEK) medium condi-
tioned by untransfected HEK293 cells; (pre-pro-GDNF/GFP) medium conditioned by HEK293 cells transfected with pre-pro-GDNF/GFP; (mGDNF) 
medium conditioned by HEK293 cells transfected with mGDNF/GFP; (recGDNF) medium fortified with recombinant GDNF (SantaCruz) diluted to a 
concentration of 2 ng/ml. Data are presented in pg/ml as mean ± SEM (n = 3). Differences between values are significant at *p < 0.01 as compared 
with all other values. **p < 0.05 as compared with HEK293. #p < 0.05 as compared with recGDNF (one-way ANOVA)
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administered MPTP alone or after transplantation with 
cells without transgenic GDNF (HEK293/GFP + MPTP).
The caudate-putamen locus where HEK293/mGDNF/
GFP and HEK293/GFP cells were injected was examined 
on the brain sections crossing the striatum using fluores-
cence microscopy. In all cases, the transplantation loci 
were in the middle part of the caudate-putamen (Fig. 6a). 
At the same time, nearly no GFP-positive cells were 
found in the stratum of experimental animals, which 
can be due to a long period of time passed after trans-
plantation. Control animals transplanted with HEK293/
mGDNF/GFP or HEK293/GFP cells were sacrificed 
3 days after transplantation. These controls demonstrated 
GFP-positive transgenic cells in the transplantation site 
(Fig. 6b). Immunohistochemical analysis using antibodies 
against GDNF demonstrated that HEK293/mGDNF/GFP 
cells expressed transgenic GDNF 3 days after transplan-
tation into the stratum (Fig. 6c).
Analysis of motor coordination
In our experiments, mice of all groups could retain on 
the rotarod at 6 rpm for 10 min. As the speed increased, 
experimental groups demonstrated substantial differ-
ences in the threshold speed of the animal falling down. 
Mice of group 1 transplanted with cells expressing modi-
fied GDNF without the pre- and pro-regions prior to 
MPTP administration demonstrated the best results 
remaining on the rotarod at 21 rpm, while mice of groups 
2 and 4 transplanted with cells without the GDNF gene 
or not transplanted fell down at the speed of 12–14 rpm 
(Fig. 7). The results for group 1 significantly differed from 
those for groups 4 and 2 (p < 0.05).
EEG and behavioral analysis
EEG was recorded 7 and 14  days after MPTP adminis-
tration. The injection of this proneurotoxin into control 
mice (group 4) gradually increased the wake time and 
decreased the NREM sleep time during the dark period. 
These changes observed on day 7 became significant 
by the day 14 (Figs. 4, 5a). The REM sleep time did not 
significantly change and demonstrated only a trend to 
decrease. No notable changes were observed during the 
light period (Fig. 8).
Transplantation of transgenic HEK293/mGDNF/
GFP cells into animals of group 1 prior to MPTP injec-
tion dampened these effects (Fig. 9b). If cells without the 
GDNF gene were transplanted (group 2), no dampening 
was observed, and the pattern of changes was similar 
to that of group 4 (Fig. 9c). Animals of group 3 demon-
strated no significant differences from the baseline of 
group 4 (Fig. 9d).
Discussion
The capacity of GDNF to induce axonal growth in neu-
ronal precursors in  vivo suggests that it can be used to 
inhibit neurodegenerative process and prevent neuronal 
Fig. 2 Percentage of PC12 cells with axons after 3-day culture in media conditioned by transgenic cells or in control media. (recGDNF) medium 
fortified with 1.25 ng/ml pre-pro-GDNF (SantaCruz); (HEK293/mGDNF) medium conditioned by HEK293/mGDNF/GFP with mGDNF/GFP adjusted 
to 1.25 ng/ml; (HEK293) medium conditioned by untransformed HEK293 cells; (control medium) unconditioned medium—serum-free DMEM. 
*p < 0.05 as compared with HEK293 and control medium
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death following ischemic stroke or during neurodegen-
erative diseases [2–5, 7, 8, 26]. However, clinical trials in 
Parkinson’s disease patients after intracerebroventricu-
lar administration of recombinant GDNF demonstrated 
minor or no clinical improvements. A significant effect 
was initially observed after a direct infusion of recom-
binant GDNF into the striatum [32]; however, it has not 
been confirmed by a phase II double-blind trial con-
ducted by Amagen so further clinical trials were dis-
continued. Nevertheless, well-documented protective 
properties of GDNF tempt both scientific and pharma 
specialists to find a way to using it as a neurodegenerative 
drug. For instance, MedGenesis Therapeutix and Pfizer 
made an agreement for joint development of methods for 
GDNF application and the convection enhanced delivery 
method in Parkinson’s disease.
One of possible approaches is a change of recombi-
nant GDNF molecule through a modification of the vec-
tor bearing its gene. The presence of 2 splice variants of 
the matrix RNA of GDNF gene can indicate their dif-
ferent functions [33–36]. In our pervious study [1] we 
have studied the cell secretion and functional activity 
of various GDNF isoforms. For this purpose, we trans-
fected HEK293 cells using plasmid constructions involv-
ing 4 different GDNF gene isoforms: a modification with 
pre- and pro-sequences (pre-pro-Gdnf); modification 
with pre- sequence only (pre-Gdnf); modification with 
pro- sequence only (pro-Gdnf); modification without 
both pre- and pro-sequences (mGdnf). In  vitro experi-
ments demonstrated that deleting pro-sequences as well 
as simultaneous deleting both pre- and pro-sequences of 
GDNF do not prevent the factor’s secretion by the cell 
and do not decrease its neurotrophic activity.
Here, we used ELISA to demonstrate a substantial 
and significant improvement in the release of transgenic 
GDNF without pre- and pro-regions from transfected 
cells compared to that with intact pre- and pro-regions. 
In  vitro experiments on PC12 cells demonstrated that 
Fig. 3 PC12 cells immunocytochemically stained for β-tubulin after culture in media conditioned by transgenic cells or in control media. (pre-pro-
GDNF) media conditioned by HEK293 cells transfected with pre-pro-GDNF/GFP; (mGDNF) media conditioned by HEK293 cells transfected with 
mGDNF/GFP and mGDNF/GFP; (control medium) unconditioned medium—serum-free DMEM; (HEK) media conditioned by untransfected HEK293. 
Cells cultured in media conditioned by transfected cultures demonstrate a significantly higher proportion of cells with axons. Scale 100 µm (right 
lower corner)
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the differentiation activity of transgenic GDNF with 
deleted pre- and pro-regions is as high as that of recom-
binant GDNF with intact pre- and pro-regions. So GDNF 
can be secreted from the cell even at the absence of the 
sequences which are necessary for regulation of the pro-
cess of its secretion. Uncontrolled intensive secretion of 
GDNF may be useful for the construction of gene-cel-
lular therapeutic drugs if the high concentration of the 
gene product must be achieved at the site of transgenic 
cell transplantation. The data obtained suggest that the 
genetic constructs containing GDNF with deleted pre- 
and pro-regions can become more efficient in gene ther-
apy compared to full-length GDNF variants.
Important advantage of gene-deleted constructions 
without pre- and pro-sequences is inability to secret-
ing GDNF pro-forms from the transgenic cells. Mature 
forms of many neurotrophic factors (NGF, BDNF, NT3) 
realize their neuroprotective and differential activity via 
tyrosine kinase receptors (TrkA, TrkB and TrkC). At the 
same time their pro-forms which may be also synthesized 
and secreted from neurons and glia induce apoptosis via 
p75NTR-sortilin signaling cascades [37–41]. Regarding 
the GDNF, it is known that in a case of overexpression 
after plasmid transfection unprocessed proGDNF can 
be also secreted from the cell [17, 42]. proGDNF activ-
ity in the brain is insufficiently studied, however it is 
known that its expression increased in the ventral part of 
midbrain in MPTP mouse model of Parkinson’s disease. 
In rat LPS model, proGDNF is expressed in nigral neu-
rons and glia [43]. One may propose that proGDNF may 
be involved into pathogenesis of Parkinson’s disease and 
does not counteract pathological disorders. In this case 
the lack of the pro-sequence in a transgene will be in 
favor of the therapeutic effect of transfected cells.
The main purpose of the study is to check up neuro-
protective properties of mGDNF construction in  vivo 
when the mature protein is secreted not to the cultural 
but the active intercellular medium. We used the mouse 
MPTP model of Parkinson’s disease to evaluate neu-
roprotective properties of the construct with mGDNF 
in vivo. MPTP injection considerably decreased the num-
ber of TH+ neurons in the ventral midbrain of experi-
mental animals. The transplantation of transgenic cells 
with the GDNF gene lacking the pre- and pro-regions 
into the caudate-putamen of mice 3 days prior to MPTP 
injection substantially neutralized the negative impact of 
the proneurotoxin. Under these conditions, the MPTP 
induced a smaller decrease in the number of TH+ neu-
rons in experimental animals compared to those trans-
planted with no cells or cells expressing no transgenic 
GDNF. It should be noted, after all, that the transplan-
tation of HEK293 cells containing no transgenic GDNF 
prior to MPTP administration also has some neuropro-
tective effect on dopaminergic neurons in the substantia 
nigra pars compacta and the ventral tegmental area. This 
is indicated by a significant increase in calculated TH+ 
neurons as compared to animals not subjected to trans-
plantation. A similar protective effect of untransfected 
cells was described by Cunningham and Su [12]. Follow-
ing the authors, one can putatively attribute this effect 
Fig. 4 Representative micrographs of coronal sections of the ventral midbrain in an intact and MPTP treated animals. a Intact mouse, b a mouse 
after MPTP injection; c a mouse transplanted with HEK293/mGDNF/GFP cells 3 days prior to MPTP injection; d a mouse transplanted with HEK293/
GFP cells 3 days prior to MPTP injection. Scale 500 µm (right lower corner)
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Fig. 5 TH+ neuron counts in the ventral midbrain (SNC and VTA) in intact and MPTP treated animals. a TH+ neuron counts in the substantia nigra 
pars compacta. b TH+ neuron counts in the ventral tegmental area. c Total number of TH+ neuron in ventral midbrain. (MPTP) group 4 animals 
injected with MPTP only; (HEK293/mGDNF + MPTP) group 1 animals transplanted with HEK293/mGDNF/GFP 3 days prior to MPTP injection; 
(HEK293 + MPTP) group 2 animals transplanted with HEK293/GFP cells prior to MPTP injection. *p < 0.05 as compared with MPTP only and HEK293/
GFP. #p < 0.05 as compared with MPTP only
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to a weak trophic impact of injected cells or to the effect 
of factors released by brain cells injured by injection of a 
large volume of cells.
The test on rotating rod (rotarod) is conventionally 
used to evaluate functional disturbances in this model 
[20]. This test demonstrated a smoothing of MPTP effect 
on the motor abilities of experimental animals after 
the transplantation of cells transfected with the GDNF 
gene without the pre- and pro-sequences. A minor 
attenuation of MPTP effect was also observed after the 
transplantation of cells without GDNF into the striatum; 
however, this effect did not significantly differ from con-
trol with MPTP injection without cell transplantation.
We also evaluated the effect of cells releasing GDNF 
without the pre- and pro-regions on the non-motor con-
sequences of MPTP administration described previously 
[23]. In present experiments as well as the cited publica-
tion, mice demonstrated increased motor activity, elon-
gated total wake time, and shortened NREM and REM 
sleep time during the darkness (period of diurnal activity) 
Fig. 6 The time-dependent mGDNF level in the striatum after HEK/mGDNF/GFP transplantation. a–c Representative fluorescence micrographs of 
coronal sections of the striatum in the transplantation site. a GFP-expressing cells were almost missing in the injection site (indicated by the arrow) 
in the caudate-putamen of animals sacrificed 19 days after transplantation of transgenic cells containing the modified GDNF. One can see two GFP-
expressing cells. b mGDNF/GFP-producing cells 3 days after transplantation into the striatum of mouse brain. c The same section immunohisto-
chemically stained for GDNF (visualized by Texas red-conjugated secondary antibodies). Scale in a 1 mm, in b, c (shown on c) 200 μm. d The results 
of Western blot analysis of mGDNF/GFP expression in striatum 2, 3, 5, 18 days after cell administration
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within two weeks after systemic MPTP administration. 
These changes are observed in the same circadian period 
of pineal melatonin production when the correspond-
ing sleep disorders are observed in Parkinson’s disease 
patients [24]. The transplantation of cells with transgenic 
GDNF lacking the pre- and pro-regions into the striatum 
3 days prior to MPTP administration efficiently antago-
nized these changes. In contrast to the MPTP control, 
the sleep-wake ratio during the dark period was the same 
on days 7 and 14. At the same time, the transplantation 
of control HEK293/GFP cells into the same striatum 
region had no effect on the MPTP-induced changes in 
the sleep-wakefulness cycle (group 2). The transplanta-
tion of transgenic mGDNF-expressing cells without sub-
sequent MPTP administration also had no effect on the 
sleep-wakefulness cycle (group 3). It may be concluded 
that namely the GDNF protein released by HEK293/
mGDNF/GFP cells is the factor antagonizing the neuro-
toxic impact of MPTP in our experiments (group 1).
Non-motor manifestations of Parkinson’s disease 
attract increasing attention since it is becoming more 
and more clear that their understanding can contribute 
to early diagnosis of this illness [44]. Such manifesta-
tions of Parkinson’s disease include sleep disorders night-
time insomnia, daytime sleepiness, and REM behavior 
disorders, which are early predictors of Parkinson’s dis-
ease that can appear years or even decades before motor 
disturbances [22]. The data obtained in this work dem-
onstrate that analysis of the changes in sleep-waking 
cycle is an adequate approach to verify early stages of 
Parkinson’s disease in model animals as well as to test 
Fig. 7 Rotarod test of mice of groups 1, 2, and 4. The results for mice 
of group 4 injected with MPTP only (MPTP, N = 11), group 2 trans-
planted with HEK293/GFP cells prior to MPTP injection (HEK + MPTP, 
N = 10), and group 1 transplanted with HEK293/mGDNF/GFP cells 
prior to MPTP injection (mGDNF + MPTP, N = 10). Ordinate, rotarod 
speed when animals fell down after a 30 s exposure normalized to 
group 4 (100 %), mean ± SEM. *Difference from group 4 significant 
at p < 0.05
Fig. 8 Changes in the sleep-wakefulness cycle in group 4 mice after administration of proneurotoxin MPTP. Percentage (12 h = 100 %) of wake 
time (blue bars), NREM sleep time (brown bars), and REM sleep time (green bars) during the light and dark (shaded rectangle) 12-h periods before 
(baseline) as well as 7 and 14 days after MPTP administration. *Changes from baseline significant at p < 0.01 (N = 9)
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anti-Parkinson’s disease effects of various biochemical 
factors.
Conclusions
Thus, transplantation of transgenic cells with the GDNF 
gene lacking the pre- and pro-sequences can protect 
dopaminergic neurons in the mouse midbrain from the 
influence of subsequent administration of the proneuro-
toxin MPTP, which is confirmed by polysomnographic, 
behavioral (rotarod) and histochemical data. This work 
confirms our previous data that the product of the con-
struct bearing the GDNF gene without the pre- and pro-
sequences is not only released from transfected cells but 
also preserves the neurotrophic, differentiation, and neu-
roprotective properties.
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